PLX4032

PLX4032

CAT N°: 10618
Price:

From 66.00 56.10

PLX4032 is an orally bioavailable, ATP-competitive inhibitor of mutant V600E and wild type B-Raf kinases (IC50s = 31 and 100 nM, respectively).{27947} It inhibits cell proliferation in a variety of cell lines expressing B-Raf V600E and synergizes strongly with taxol, vinblastine, and oxaliplatin in inhibiting the proliferation of B-RafV600E transformed cancer cells.{27947} PLX4032 is effective against the growth of tumors bearing the B-Raf V600E mutation.{18549,18645,27944,27852}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-[3-[[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-propanesulfonamide
  • Correlated keywords
    • biochemical inhibitor cancer signal transduction intracellular kinase protein 1029872-54-5 mutant V600E wild type B-Raf BRaf BRafV600E B-RafV600E PLX-4032 bioavailable ATP-competitive inhibit cell proliferation synergize taxol vinblastine oxaliplatin transformed mutation
  • Product Overview:
    PLX4032 is an orally bioavailable, ATP-competitive inhibitor of mutant V600E and wild type B-Raf kinases (IC50s = 31 and 100 nM, respectively).{27947} It inhibits cell proliferation in a variety of cell lines expressing B-Raf V600E and synergizes strongly with taxol, vinblastine, and oxaliplatin in inhibiting the proliferation of B-RafV600E transformed cancer cells.{27947} PLX4032 is effective against the growth of tumors bearing the B-Raf V600E mutation.{18549,18645,27944,27852}

We also advise you